EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract

Tianyang Mao, Jooyoung Kim, Mario A Peña-Hernández, Gabrielee Valle, Miyu Moriyama, Sophia Luyten, Isabel M Ott, Maria Luisa Gomez-Calvo, Jeff R Gehlhausen, Emily Baker, Benjamin Israelow, Martin Slade und 15 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2319566121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Tianyang Mao und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06510. Hauptthemen laut MEDLINE: Neomycin, Administration, Intranasal, Antiviral Agents, SARS-CoV-2. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Bill and Melinda Gates Foundation (GF), Howard Hughes Medical Institute (HHMI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory virus infections in humans cause a broad-spectrum of diseases that result in substantial morbidity and mortality annually worldwide. To reduce the global burden of respiratory viral diseases, preventative and therapeutic interventions that are accessible and effective are urgently needed, especially in countries that are disproportionately affected. Repurposing generic medicine has the potential to bring new treatments for infectious diseases to patients efficiently and equitably. In this study, we found that intranasal delivery of neomycin, a generic aminoglycoside antibiotic, induces the expression of interferon-stimulated genes (ISGs) in the nasal mucosa that is independent of the commensal microbiota. Prophylactic or therapeutic administration of neomycin provided significant protection against upper respiratory infection and lethal disease in a mouse model of COVID-19. Furthermore, neomycin treatment protected Mx1 congenic mice from upper and lower respiratory infections with a highly virulent strain of influenza A virus. In Syrian hamsters, neomycin treatment potently mitigated contact transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In healthy humans, intranasal application of neomycin-containing Neosporin ointment was well tolerated and effective at inducing ISG expression in the nose in a subset of participants. These findings suggest that neomycin has the potential to be harnessed as a host-directed antiviral strategy for the prevention and treatment of respiratory viral infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeomycinAdministration, IntranasalAntiviral AgentsSARS-CoV-2AnimalsMiceHumansCOVID-19Respiratory Tract InfectionsNasal MucosaDisease Models, AnimalCOVID-19 Drug TreatmentMesocricetusFemaleInfluenza A virus

Stichwörter der Autor:innen

antiviralinterferonmucosal immunitynasaltransmission

Substanzen

NeomycinAntiviral Agents

Autor:innen und Institutionen

  • Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06510.
  • Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT 06510.
  • Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh PA 15213.
  • Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven CT 06510.
  • Department of Dermatology, Yale University School of Medicine, New Haven, CT 06510.
  • Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06510.

ORCID-Profile: Valter Silva Monteiro, Smita Gopinath, Craig B Wilen, Akiko Iwasaki

Förderung

  • NCATS NIH HHS
  • Bill and Melinda Gates Foundation (GF)
  • Howard Hughes Medical Institute (HHMI)

Zitieren

APA

Mao, T., Kim, J., Peña-Hernández, M. A., Valle, G., Moriyama, M., Luyten, S., Ott, I. M., Gomez-Calvo, M. L., Gehlhausen, J. R., Baker, E., Israelow, B., Slade, M., Sharma, L., Liu, W., Ryu, C., Korde, A., Lee, C. J., Silva Monteiro, V., Lucas, C., …, & Iwasaki, A. (2024). Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2319566121

Vancouver

Mao T, Kim J, Peña-Hernández MA, Valle G, Moriyama M, Luyten S, et al. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2319566121

BibTeX
@article{Mao2024,
  author = {Mao, Tianyang and Kim, Jooyoung and Peña-Hernández, Mario A and Valle, Gabrielee and Moriyama, Miyu and Luyten, Sophia and Ott, Isabel M and Gomez-Calvo, Maria Luisa and Gehlhausen, Jeff R and Baker, Emily and Israelow, Benjamin and Slade, Martin and Sharma, Lokesh and Liu, Wei and Ryu, Changwan and Korde, Asawari and Lee, Chris J and Silva Monteiro, Valter and Lucas, Carolina and Dong, Huiping and Yang, Yi and Yale SARS-CoV-2 Genomic Surveillance Initiative, Yale SARS-CoV-2 Genomic Surveillance Initiative and Gopinath, Smita and Wilen, Craig B and Palm, Noah and Dela Cruz, Charles S and Iwasaki, Akiko},
  title = {Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2319566121}
}
Kostenlos starten →